This trial is evaluating whether ZN-c3 will improve 1 primary outcome and 3 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of 2 years.
This trial requires 110 total participants across 2 different treatment groups
This trial involves 2 different treatments. ZN-c3 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Carcinoma develops when cells undergo transformation. This depends partly on genetic factors, and partly on external influences. The environmental agents that initiate transformation have not yet been definitely identified. The risk factors for carcinoma of any type include advancing age and cigarette smoking.
The number of available treatments is very vast, depending on the type of carcinoma and the type, severity, or stage of the disease. The following is a brief summary of the main treatments available for carcinoma.
Carcinoma is a cancer typically associated with cancer of the body or the cervix. Although the word ‘carcinoma’ only appears in medical dictionaries once a year, cancer is one of the most important diseases affecting the world’s population.
Findings from a recent study implies that a low dose (5 Gy) is sufficient for treatment of carcinoma without a relapse and survival rate. However, low dose RT should not be applied to patients with a poor performance status.
Carcinoma a year is very rare in the United Kingdom or the United States. On the basis of the US national death register, one in 400,000 people in the United States dies each year aged 70 years or over from the cancer. On the basis of the UK national cancer register, one in 350 people in England dies from the cancer.
The signs of carcinoma include a mass or lump on the surface of the body, a mass in the lumen of the bladder, and a mass in the rectum.
The survival rate of the patients with carcinoma is 1% 5 years from the time of onset; 1% 3 years from the time of diagnosis; and 4% 5 years from the time of diagnosis. Data from a recent study support the notion that the time from symptom onset to death of patients with carcinoma is relatively distant and that the initial treatment could be considered to be effective.
We conclude that there is increased spread of carcinoma at initial presentation over time, and this justifies early histopathological confirmation of carcinoma at diagnosis and close outpatient follow-up of patients with carcinoma.
In a population with no hereditary and non-environmental factors, the principal risk factor for carcinoma is smoking; this does not include secondhand or third hand smoking. Carcinoma can be prevented by the use of the WHO (World Health Organisation) recommendations.\n
Zn-c3 is effective in improving HRQoL in patients with carcinoma. This improvement has been seen by the time the patient had reached the stage of advanced malignancy.
Results from a recent clinical trial suggest that the use of Zn-C3 in combination with radiation or chemotherapy should be limited to local indications since its effects in a distant site(s) is not expected to improve disease-free survival, PFS, or OS.